MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$127,767
Free Cash flow
-$7,874,647
Unit: Dollar
Positive Cash Flow Breakdown
Goodwill impairment
Proceeds from notes payable
Non-cash stock-based compensatio...
Others
Negative Cash Flow Breakdown
Net loss
Change in fair value of continge...
Repayments of finance agreement
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-06-30
Intangible asset impairment
0
Loss on extinguishment of debt
0
Goodwill impairment
170,419,429
Change in fair value of contingent consideration
11,680,000
Change in fair value of equity securities
112,149
Net loss
-178,007,489
Depreciation and amortization
129,095
Non-cash stock-based compensation expense
3,313,291
Non-cash restricted shares issued for services rendered
1,946,845
Amortization of discount on note payable
32,024
Other receivables
-1,153,768
Prepaid expenses/deposits
-1,143,293
Accounts payable
3,106,181
Other current liabilities
-26,477
Operating leases, net
-16,086
Accrued expenses
499,330
Net cash used in operating activities
-7,874,647
Purchase of property and equipment
0
Investment in equity securities
500,000
Notes receivable prior to acquisition
0
Cash received from acquisition, net
0
Net cash used in investing activities
-500,000
Proceeds from exercise of warrants
0
Repayments of finance agreement
971,231
Proceeds from private placements
2,376,181
Proceeds from issuance of promissory notes
0
Proceeds from notes payable
6,977,822
Net cash provided by financing activities
8,382,772
Effect of exchange rates on cash
-135,892
Net increase (decrease) in cash
-127,767
Cash and cash equivalents at beginning of period
220,467
Cash and cash equivalents at end of period
92,700
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from notes
payable
$6,977,822
Proceeds from private
placements
$2,376,181
Net cash provided by
financing activities
$8,382,772
Canceled cashflow
$971,231
Net increase
(decrease) in cash
-$127,767
Canceled cashflow
$8,382,772
Goodwill impairment
$170,419,429
Non-cash stock-based
compensation expense
$3,313,291
Accounts payable
$3,106,181
Non-cash restricted
shares issued for...
$1,946,845
Other receivables
-$1,153,768
Prepaid
expenses/deposits
-$1,143,293
Accrued expenses
$499,330
Depreciation and
amortization
$129,095
Change in fair value of
equity securities
$112,149
Amortization of discount on
note payable
$32,024
Repayments of finance
agreement
$971,231
Net cash used in
operating activities
-$7,874,647
Canceled cashflow
$181,855,405
Net cash used in
investing activities
-$500,000
Effect of exchange
rates on cash
-$135,892
Net loss
-$178,007,489
Change in fair value of
contingent consideration
$11,680,000
Other current
liabilities
-$26,477
Operating leases, net
-$16,086
Investment in equity
securities
$500,000
Buy us a coffee
Lunai Bioworks Inc. (RENB)
Lunai Bioworks Inc. (RENB)